Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA

被引:31
|
作者
Peletskaya, EN
Kogon, AA
Tuske, S
Arnold, E
Hughes, SH
机构
[1] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA
[2] NCI, SAIC Frederick, Frederick, MD 21702 USA
[3] Rutgers State Univ, Dept Chem & Biol Chem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA
关键词
D O I
10.1128/JVI.78.7.3387-3397.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Site-directed photoaffinity cross-linking experiments were performed by using human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) mutants with unique cysteine residues at several positions (i.e., positions 65, 67, 70, and 74) in the fingers subdomain of the p66 subunit. Since neither the introduction of the unique cysteine residues into the fingers nor the modification of the SH groups of these residues with photoaffinity cross-linking reagents caused a significant decrease in the enzymatic activities of RT, we were able to use this system to measure distances between specific positions in the fingers domain of RT and double-stranded DNA. HIV-1 RT is quite flexible. There are conformational changes associated with binding of the normal substrates and nonnucleoside RT inhibitors (NNRTIs). Cross-linking was used to monitor intramolecular movements associated with binding of an NNRTI either in the presence or in the absence of an incoming deoxynucleoside triphosphate (dNTP). Binding an incoming dNTP at the polymerase active site decreased the efficiency of cross-linking but caused only modest changes in the preferred positions of cross-linking. This finding suggests that the fingers of p66 are closer to an extended template in the "open" configuration of the enzyme with the fingers away from the active site than in the closed configuration with the fingers in direct contact with the incoming dNTP. NNRTI binding caused increased cross-linking in experiments with diazirine reagents (especially with a diazirine reagent with a longer linker) and a moderate shift in the preferred sites of interaction with the template. Cross-linking occurred closer to the polymerase active site for RTs modified at positions 70 and 74. The effects of NNRTI binding were more pronounced in the absence of a bound dNTP; pretreatment of HIV-1 RT with an NNRTI reduced the effect of dNTP binding. These observations can be explained if the binding of NNRTI causes a decrease in the flexibility in the fingers subdomain of RT-NNRTI complex and a decrease in the distance from the fingers to the template extension.
引用
收藏
页码:3387 / 3397
页数:11
相关论文
共 50 条
  • [21] Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    Hachiya, Atsuko
    Kodama, Eiichi N.
    Sarafianos, Stefan G.
    Schuckmann, Matthew M.
    Sakagami, Yasuko
    Matsuoka, Masao
    Takiguchi, Masafumi
    Gatanaga, Hiroyuki
    Oka, Shinichi
    JOURNAL OF VIROLOGY, 2008, 82 (07) : 3261 - 3270
  • [22] Human immunodeficiency virus type 1 reverse transcriptase
    Hottiger, M
    Hubscher, U
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1996, 377 (02): : 97 - 120
  • [23] A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR ACTIVE ON HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES RESISTANT TO RELATED INHIBITORS
    GOLDMAN, ME
    OBRIEN, JA
    RUFFING, TL
    SCHLEIF, WA
    SARDANA, VV
    BYRNES, VW
    CONDRA, JH
    HOFFMAN, JM
    EMINI, EA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) : 947 - 949
  • [24] Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1
    Szczech, GM
    Furman, P
    Painter, GR
    Barry, DW
    Borroto-Esoda, K
    Grizzle, TB
    Blum, MR
    Sommadossi, JP
    Endoh, R
    Niwa, T
    Yamamoto, M
    Moxham, C
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) : 123 - 130
  • [25] Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats
    Chang, M
    Sood, VK
    Wilson, GJ
    Kloosterman, DA
    Sanders, PE
    Hauer, MJ
    Fagerness, PE
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (02) : 228 - 242
  • [26] CHARACTERIZATION OF THE BINDING-SITE FOR NEVIRAPINE (BI-RG-587), A NONNUCLEOSIDE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
    COHEN, KA
    HOPKINS, J
    INGRAHAM, RH
    PARGELLIS, C
    WU, JC
    PALLADINO, DEH
    KINKADE, P
    WARREN, TC
    ROGERS, S
    ADAMS, J
    FARINA, PR
    GROB, PM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (22) : 14670 - 14674
  • [27] SELECTIVE AND SYNERGISTIC INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE BY A NONNUCLEOSIDE INHIBITOR, MKC-442
    YUASA, S
    SADAKATA, Y
    TAKASHIMA, H
    SEKIYA, K
    INOUYE, N
    UBASAWA, M
    BABA, M
    MOLECULAR PHARMACOLOGY, 1993, 44 (04) : 895 - 900
  • [28] Human immunodeficiency virus mutagenesis during antiviral therapy: Impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies
    Chen, RX
    Yokoyama, M
    Sato, H
    Reilly, C
    Mansky, LA
    JOURNAL OF VIROLOGY, 2005, 79 (18) : 12045 - 12057
  • [29] Etravirine and Rilpivirine: Nonnucleoside Reverse Transcriptase Inhibitors with Activity Against Human Immunodeficiency Virus Type 1 Strains Resistant to Previous Nonnucleoside Agents
    Fulco, Patricia Pecora
    McNicholl, Ian R.
    PHARMACOTHERAPY, 2009, 29 (03): : 281 - 294
  • [30] A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation
    Fan, NS
    Rank, KB
    Slade, DE
    Poppe, SM
    Evans, DB
    Kopta, LA
    Olmsted, RA
    Thomas, RC
    Tarpley, WG
    Sharma, SK
    BIOCHEMISTRY, 1996, 35 (30) : 9737 - 9745